Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C

Hepatology Research

Volumn 42, Issue 7, 2012, Pages 714-720

  Cobbold, Jeremy F L ^a   Cox, I Jane ^a,b   Brown, Ashley S ^a   Williams, Horace R T ^a   Goldin, Robert D ^a   Thomas, Howard C ^a   Thursz, Mark R ^a   Taylor Robinson, Simon D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF HEPATOLOGY   (United Kingdom)

Author keywords

Hepatitis C; Lipid; Liver; Magnetic resonance spectroscopy; Steatosis; Sustained virological response

Indexed keywords

CHOLINE; LIPID; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HEPATITIS C; HUMAN; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIVER; LIVER BIOPSY; LIVER HISTOLOGY; MALE; PREDICTION; PRIORITY JOURNAL; PROTON MAGIC ANGLE SPINNING MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; STEATOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84862260930     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.00975.x     Document Type: Article

References (38)

1. Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. Hepatitis C and hepatic steatosis. QJM 2010 (Feb); 103: 293-303.
2. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
3. Rubbia-Brandt L, Fabris P, Paganin S etal. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004 (Mar); 53 (3): 406-12.
4. Cross TJ, Quaglia A, Hughes S, Joshi D, Harrison PM. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat 2009 (Jul); 16 (7): 492-9.
5. Reddy KR, Govindarajan S, Marcellin P etal. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat 2008 (Feb); 15 (2): 129-36.
6. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 2005 (Feb); 102 (7): 2561-6.
7. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 (Jun); 41 (6): 1313-21.
8. Ishak K, Baptista A, Bianchi L etal. Histological grading and staging of chronic hepatitis. J Hepatol 1995 (Jun); 22 (6): 696-9.
9. Cobbold JF, Anstee QM, Goldin RD etal. Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. Clin Sci (Lond) 2009 (Mar); 116 (5): 403-13.
10. Cobbold JF, Patel JH, Goldin RD etal. Hepatic lipid profiling in chronic hepatitis C: an in vitro and in vivo proton magnetic resonance spectroscopy study. J Hepatol 2010 (Jan); 52 (1): 16-24.
11. Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006; 23: 1043-54.
12. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 (Sep); 347 (13): 975-82.
13. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004 (May); 350 (22): 2265-71.
14. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000 (Jan); 31 (1): 211-8.
15. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009 (Sep); 461 (7262): 399-401.
16. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 (Apr); 49 (4): 1335-74.
17. Martinez-Granados B, Monleon D, Martinez-Bisbal MC etal. Metabolite identification in human liver needle biopsies by high-resolution magic angle spinning 1H NMR spectroscopy. NMR Biomed 2006 (Feb); 19 (1): 90-100.
18. Bollard ME, Garrod S, Holmes E etal. High-resolution (1)H and (1)H-(13)C magic angle spinning NMR spectroscopy of rat liver. Magn Reson Med 2000 (Aug); 44 (2): 201-7.
19. Duarte IF, Stanley EG, Holmes E etal. Metabolic assessment of human liver transplants from biopsy samples at the donor and recipient stages using high-resolution magic angle spinning 1H NMR spectroscopy. Anal Chem 2005; 77: 5570-8.
20. Rooney OM, Troke J, Nicholson JK, Griffin JL. High-resolution diffusion and relaxation-edited magic angle spinning 1H NMR spectroscopy of intact liver tissue. Magn Reson Med 2003 (Nov); 50 (5): 925-30.
21. Yao ZM, Vance DE. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem 1988 (Feb); 263 (6): 2998-3004.
22. Noga AA, Zhao Y, Vance DE. An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J Biol Chem 2002; 277: 42358-65.
23. Walkey CJ, Yu L, Agellon LB, Vance DE. Biochemical and evolutionary significance of phospholipid methylation. J Biol Chem 1998; 273: 27043-6.
24. Cabre E, Gassull MA. Polyunsaturated fatty acid deficiency in liver diseases: pathophysiological and clinical significance. Nutrition 1996 (Jul); 12 (7-8): 542-8.
25. Serkova NJ, Jackman M, Brown JL etal. Metabolic profiling of livers and blood from obese Zucker rats. J Hepatol 2006 (May); 44 (5): 956-62.
26. Puri P, Baillie RA, Wiest MM etal. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007 (Oct); 46 (4): 1081-90.
27. Okuda M, Li K, Beard MR etal. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002 (Feb); 122 (2): 366-75.
28. Paradis V, Mathurin P, Kollinger M etal. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997 (May); 50 (5): 401-6.
29. Diamond DL, Jacobs JM, Paeper B etal. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology 2007 (Sep); 46 (3): 649-57.
30. Miyoshi H, Moriya K, Tsutsumi T etal. Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. J Hepatol 2011 (Mar); 54 (3): 432-8.
31. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002 (Apr); 346 (16): 1221-31.
32. Poustchi H, Negro F, Hui J etal. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008 (Jan); 48 (1): 28-34.
33. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 2001; 98: 9599-604.
34. Shintani Y, Fujie H, Miyoshi H etal. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004 (Mar); 126 (3): 840-8.
35. Walsh MJ, Jonsson JR, Richardson MM etal. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006 (Apr); 55 (4): 529-35.
36. Huang Y, Feld JJ, Sapp RK etal. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 2007 (Feb); 132 (2): 733-44.
37. Persico M, Capasso M, Persico E etal. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007 (Oct); 46 (4): 1009-15.
38. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010 (Nov); 52 (5): 1836-46.